Adamax and Noopept Interaction: Monitor | Peptide Database

YK-11's dual mechanism of AR agonism and myostatin inhibition theoretically positions it as a potent anabolic compound for increasing lean muscle mass. Cell culture data supports increased anabolic signaling and follistatin expression. However, there is no in vivo or clinical evidence confirming these effects in animals or humans. All efficacy reports are anecdotal. Users anecdotally report significant strength gains during YK-11 cycles, consistent with the compound's theoretical mechanism of action. The combination of AR-mediated protein synthesis and myostatin inhibition could theoretically support enhanced force production. No controlled studies exist to verify these claims. The most distinctive proposed benefit of YK-11 is its ability to upregulate follistatin and thereby inhibit myostatin-mediated limitations on muscle growth. In cell culture, YK-11 induced greater follistatin expression than DHT. If this translates to in vivo activity, it could allow muscle growth beyond normal physiological limits. This remains entirely unproven outside of cell-based assays. Follistatin has been shown in other research contexts to positively influence bone mineral density and bone formation. If YK-11's follistatin-inducing effects translate in vivo, there could be secondary benefits for bone density. This is entirely speculative and unsupported by any direct YK-11 bone data.

FDA-approved at 1mg daily for the treatment of male pattern hair loss. Demonstrated to halt progression and promote regrowth, particularly at the vertex and mid-scalp regions. Strongest clinical evidence for regrowth in the vertex region, with significant increases in hair count documented in pivotal clinical trials. Effective at slowing frontal hairline recession and maintaining mid-scalp density, though regrowth tends to be less dramatic than at the vertex. Most effective when started early in the hair loss process, before significant miniaturization has occurred. Preservation of existing hair is more reliable than regrowth of lost hair. FDA-approved at 5mg daily (Proscar) for the treatment of symptomatic BPH. Reduces prostate volume and improves urinary flow over 6-12 months of treatment. Consistently reduces prostate volume by approximately 20-30% with long-term use, alleviating obstructive urinary symptoms.